

# Quorum Sensing in *Candida albicans*: Probing Farnesol's Mode of Action with 40 Natural and Synthetic Farnesol Analogs

Roman Shchepin,<sup>2,3</sup> Jacob M. Hornby,<sup>1,3</sup>  
Erin Burger,<sup>2</sup> Timothy Niessen,<sup>1</sup>  
Patrick Dussault,<sup>2</sup> and Kenneth W. Nickerson<sup>1,\*</sup>

<sup>1</sup>School of Biological Sciences and

<sup>2</sup>Department of Chemistry

University of Nebraska

Lincoln, Nebraska 68588

## Summary

The dimorphic fungus *Candida albicans* produces extracellular farnesol (3,7,11-trimethyl-2,6,10-dodecatriene-1-ol) which acts as a quorum-sensing molecule (QSM) to suppress filamentation. Of four possible geometric isomers of farnesol, only the *E,E* isomer possesses QSM activity. We tested 40 natural and synthetic analogs of farnesol for their activity in an *N*-acetylglucosamine-induced differentiation assay for germ tube formation (GTF). Modified structural features include the head group, chain length, presence or absence of the three double bonds, substitution of a backbone carbon by S, O, N, and Se heteroatoms, presence or absence of a 3-methyl branch, and the bulkiness of the hydrophobic tail. Of the 40 compounds, 22 showed QSM activity by their ability to reduce GTF by 50%. However, even the most active of the analogs tested had only 7.3% of the activity of *E,E*-farnesol. Structure-activity relationships were examined in terms of the likely presence in *C. albicans* of a farnesol binding receptor protein.

## Introduction

The dimorphic fungus *Candida albicans* is the first eukaryotic system shown to possess quorum-sensing behavior [1]. Quorum sensing has been thoroughly described in prokaryotes but had not been demonstrated in eukaryotes until recently. With this phenomenon, a secreted compound accumulates to a critical concentration in the medium and then acts back on the producing cells to elicit a physiological response. For Gram-negative bacteria, the quorum-sensing molecules are all members of a family of compounds known as acyl homoserine lactones [2]. In the case of *C. albicans*, the quorum-sensing molecule (QSM) is the sesquiterpene farnesol (3,7,11-trimethyl-2,6,10-dodecatriene-1-ol). Accumulation of farnesol blocks the morphological shift from yeasts to mycelia [1]. Farnesol blocks germ tube formation as triggered by serum, proline, or *N*-acetylglucosamine, and it is produced by and active on all (five) strains of *C. albicans* tested [1].

The effect of farnesol concerned morphological choice, not growth rate. At concentrations of up to 250  $\mu\text{M}$ , farnesol did not alter the growth rate for *C. albicans*; actively budding yeasts were observed in all cases [1].

This finding was confirmed by Ramage et al. [3] who observed unimpaired growth rates up to 300  $\mu\text{M}$  farnesol. The yeast-mycelia transition is critical for pathogenicity, and *C. albicans* mutants limited to the yeast morphology are avirulent [4]. A follow-up question based on this discovery is to identify farnesol's mode of action in blocking germ-tube formation in *C. albicans*. One way of approaching this question is to design, prepare, and assay analogs of farnesol with the expectation that comparison of the activity profiles would identify essential and extraneous structural features. There is also the possibility of synthesizing a compound with greater activity than that of farnesol. Analogues with enhanced activity could prove useful in a clinical setting for prevention or prophylaxis of candidiasis. This study looks at a series of first generation analogs of farnesol and begins to uncover the biology of the quorum-sensing response in *Candida albicans* as mediated by farnesol. To date, we have analyzed 40 analogs of farnesol. Of these, 22 show activity as determined by their ability to reduce germ tube formation by at least 50% at concentrations up to 100  $\mu\text{M}$ .

As well as gaining a better understanding of the biology of fungal quorum sensing, there are at least four practical advantages to be gained from farnesol analogs. (1) Preliminary experiments with a mouse model show no obvious toxicity from farnesol. However, if farnesol toxicity were to become a problem at higher dosages or with prolonged treatment, it would be desirable to develop less toxic analogs that still maintain QSM activity. (2) Farnesol has limited water solubility. Modifications of the structure of farnesol might lead to active compounds that were more soluble and thus more easily deliverable in animal systems. (3) Analogues of farnesol might also possess improved pharmacokinetics, such as an enhanced ability to enter the blood stream via the gastrointestinal tract or peritoneum. Alternatively, since farnesol is usually excreted from animals after its conversion to farnesoic acid and dicarboxylic acids [5], specific structural changes may improve retention. Both scenarios could help maintain the analog in an available form in the host. (4) While our *in vitro* studies suggest a possible prophylactic use for farnesol, it is still unclear whether this will be seen in an animal model. Farnesol could prove to act as a virulence factor for *C. albicans*. This question was posed by Hornby et al. [1] based upon anticipated differences between *in vitro* studies performed in a glass vessel and *in vivo* studies, where cellular membranes might act as a sink for the lipophilic farnesol. If farnesol functions as a virulence factor for *C. albicans*, it would be important to develop farnesol analogs that act as antagonists of virulence.

## Results

Our previous work [1] reported that both commercial mixed isomers farnesol and 96% *E,E*-farnesol exhibited QSM activity. However, subsequent comparisons with

\*Correspondence: knickerson1@unl.edu

<sup>3</sup>These authors contributed equally to this work.

Table 1. QSM Activity of Three Commercial Samples of Farnesol

Farnesol Source	Percent <i>E,E</i> -Farnesol <sup>a</sup>	Concentration (μM) for 0% GTF <sup>b</sup>	Concentration (μM) for 50% GTF <sup>b</sup>	Calculated Concentration (μM) for 50% GTF Based on Percent <i>E,E</i> -Farnesol <sup>c</sup>
Sigma <i>E,E</i> -farnesol	96	7.5	1.2	1.2
Sigma mixed isomers	56	25	3.5	2.1
Across mixed isomers	36	30	4.4	3.2

<sup>a</sup> Determined by GC/MS as previously described [1].

<sup>b</sup> Based on the regression analysis as described in Experimental Procedures.

<sup>c</sup> Calculated values of concentration that would be needed if all observed activity were due to *E,E*-farnesol only, based on the known *E,E*-farnesol content of each sample.

freshly opened bottles of farnesol showed significantly greater activity with the *E,E* isomer (Table 1) and differing activities with mixed isomers farnesol from different suppliers (Table 1). Ninety-six percent *E,E*-farnesol reduced GTF to fifty percent at 1.2 μM, with complete inhibition at ca. 7.5 μM (Table 1) while mixed isomers farnesol from Sigma (St Louis, MO) and Acros Organics (Pittsburgh, PA) reduced germ tube formation (GTF) to 50% at ca. 3.5 and 4.4 μM, respectively (Table 1). The three farnesol samples were therefore analyzed by GC/MS. The lower activity Acros mixed isomers farnesol contained only 33%–36% *E,E*-farnesol, whereas the higher activity Sigma mixed isomers farnesol contained 56% *E,E*-farnesol (Table 1). There was sufficient *E,E*-farnesol in the two mixed isomers samples to account for their QSM activities (Table 1). Based upon the percentage of *E,E*-farnesol in the Sigma and Acros Organics samples, reduction to 50% GTF would have been expected to occur at concentrations of 2.1 and 3.2 μM, respectively (Table 1). These concentrations are lower than those determined experimentally for the mixed isomers samples. Thus, it appears that only *E,E*-farnesol possesses QSM activity, and furthermore, a comparison of observed QSM activity (Table 1) with that predicted by the *E,E*-farnesol content suggests the other isomers may even act to inhibit QSM activity.

### Head Group Modifications

We tested six farnesol analogs with altered head groups (Table 2). These modifications were introduced to learn whether farnesol's C-1 hydroxyl was essential for QSM

activity. An analog was considered to be active if it was capable of reducing GTF by 50% at concentrations of ≤100 μM. In practice, this definition meant that analogs were considered active if they had ≥1% of the activity of *E,E*-farnesol. Farnesoic acid (analog 2, 3.3% relative activity) and the corresponding amide (3, 1.9%) maintained biological activity, whereas the aldehyde (4, 0.4%), bromide (5, 0.7%), methyl ester (6, 0.1%), and amine (7, 0.1%) were inactive (Table 2). The sulfhydryl analog was too insoluble to be bioassayed. In particular, farnesoic acid, which has also been identified as a QSM produced by *C. albicans* [6], displayed only 3.3% of the activity exhibited by farnesol (Table 2). With regard to farnesol's mode of action, it is significant that the hydroxyl head group is not essential for QSM activity (Table 2). This conclusion is supported by the observation of Matsuoka and Oh that β-farnesene, with no functional groups whatsoever, retained QSM activity [7].

### Double Bond Modifications

We next examined five analogs based upon alterations of the 2,3 double bond in farnesol (Table 3). The 2,3 cyclopropane ring analog (8, 3.3%) maintained biological activity, whereas the 2,3 epoxide (9, 0.4%) and 2,3 hydrogenated (10, 0.4%) analogs were inactive (Table 3). The terminal 10,11 double bond was also essential for activity in that the 10,11 hydrogenated (11, 0.3%) and fully hydrogenated (12, 0.3%) analogs were inactive (Table 3). Not unexpectedly, all-trans retinol (vitamin A), a farnesol analog with five conjugated double bonds and a bulky, cyclic tail group was also inactive (data not shown).

### Sulfur-Containing Analogs

We next tested a series of 14 analogs that incorporated sulfur atoms in place of a main chain CH<sub>2</sub> unit (Tables 4 and 5). Seven of the eight analogs with a sulfur in the 4 position retained QSM activity (Table 4) including both the *E*- and *Z*- isomers of 4-thia farnesol (13, 3.7% and 14, 3.4%, respectively). Surprisingly, the 2,3 hydrogenated 4-thia analog (15, 7.3%) retained activity (Table 4), to the extent that it was ca. 16-fold more active than the 2,3 hydrogenated analog (10) of farnesol itself (Table 3). The importance of the proximal 3-methyl side chain in the 4-thia series was examined (Table 4) via comparison of the methylated compound 15 with the demethylated series represented by compounds 16 (3.7%), 17 (1.5%), and 18 (1.7%). All three demethyl analogs retained activity, as did the 3,4 disulfide (19, 1.6%). We

Table 2. Biological Activity of Farnesol Analogs Based on Modified Head Groups

Analog Number	X =	IC <sub>50</sub> (μM) <sup>a</sup>	Relative Activity
1	CH <sub>2</sub> OH (Farnesol)	1.2	100.0
2	COOH (Farnesoic Acid)	36.2	3.26
3	CONH <sub>2</sub>	62.3	1.89
4	CHO (Farnesal)		0.38
5	CH <sub>2</sub> Br (Commercial <i>E,E</i> )		0.75
6	COOCH <sub>3</sub>		0.10
7	CH <sub>2</sub> NH <sub>2</sub>		0.14

<sup>a</sup> Inhibitory concentration (μM) at which germ tube formation is reduced to 50%.





Table 3. Biological Activity of Farnesol Analogs Based on Modifications to Their 2,3 Double Bond

Analog Number	Double Bond Modification	IC <sub>50</sub> (μM)	Relative Activity
1	None	1.2	100.0
8	2,3-cyclopropane	35.9	3.26
9	2,3-epoxide		0.38
10	2,3-hydrogenated		0.45
11	10,11-hydrogenated		0.31
12	Hydrogenate all three double bonds		0.31



27		68.7	1.72
28		23.2	5.08
29		24.4	4.80

can then make the comparison among three compounds (17, 15, and 20 [0.5%]) with increasingly bulky 3-side chains (Table 4); activity increases 5-fold with insertion of the 3-methyl (15 versus 17) and then decreases 16-fold with the bulkier 3-ethyl (20 versus 15).

Similarly, five of the six analogs with the sulfur atom in the 9 position also retained QSM activity (Table 5).

The 9-thia series with n-butyl (21, 4.9%), isobutyl (22, 2.6%), and t-butyl (23, 0.9%) showed decreasing activity with increased branching (Table 5). The relative inactivity of the t-butyl 9-thia analog (23) should not be due merely to greater hydrophobicity because the n-pentyl (24, 1.8%), benzyl (25, 1.7%), and phenyl (26, 1.5%) 9-thia analogs still had QSM activity (Table 5). However, it

Table 4. Biological Activity of Farnesol Analogs with Sulfur Atoms at the 4 Position

Analog Number	X =	IC <sub>50</sub> (μM)	Relative Activity
13		(trans) 32.1	3.67
14		(cis) 35.1	3.36
15		16.0	7.34
16		31.6	3.70
17		79.1	1.47
18		67.0	1.75
19		(disulfide) 72.4	1.61
20			0.48

could reflect the bulkier cross-section of the t-butyl being unable to fit into the narrow cleft of a farnesol receptor.

### Chain Length Modifications

Farnesol is a 15 carbon sesquiterpene; it has a 12 carbon chain with three methyl branches. We next examined whether altering the chain length alters QSM activity. Three demethylated, 2,3-hydrogenated analogs (**27**, 1.7%; **28**, 5.1%; and **29**, 4.8%) have chain lengths of 10–12 carbons (Table 3) and lack the 2,3 double bond and 3-methyl branch found in farnesol. Compounds **27–29** all exhibited activity, suggesting some flexibility with regard to chain lengths. This flexibility with regard to chain length was also shown by the 4-thia (Table 4) and 9-thia (Table 5) analogs. Counting S and  $-\text{CH}_2-$  as equivalent, compounds **16–18** in the 4-thia series (with chain lengths of 11–13, respectively) all had QSM activity (Table 4) as did compounds **21** and **24** in the 9-thia series (with chain lengths of 13–14, Table 5).

### Heteroatoms in the Carbon Chain

Based on our success with the sulfur-containing analogs (Tables 4 and 5), we tried a series of other heteroatoms at the 4 and 9 positions (Table 6). The 4-Se analog (**30**, 2.6%) was the only one which retained QSM activity; all the O-containing analogs and the one N-containing analog (**31**, 0.03%) were inactive (Table 6). In each case, the oxygen-containing analog was less active than the corresponding sulfur-containing analog. Compound **32** (0.1%) was 21-fold less active than **17**, compound **33** (0.5%) was 14-fold less active than **15**, compound **34** (0.4%) was 4.6-fold less active than **18**, and compound **35** (1.0%) was 2.8-fold less active than **22**.

### Hydroxyl and Epoxide Analogs of Farnesol

As seen in Table 3, the epoxide at the 2,3 position (**9**) was ca. 260-fold less active than *E,E*-farnesol. However, the epoxide at the 10,11 position (**36**, 1.7%) was still active, as were the 10-hydroxyl (**37**, 1.7%) and 6-hydroxyl (**38**, 1.5%) analogs (Table 7). The 10,11 epoxide of farnesol is, of course, the reduced form of insect juvenile hormone III (**39**) which has a methyl ester at the C-1 position instead of the hydroxyl in farnesol. Thus, the QSM inactivity of juvenile hormone III (**39**) is expected from the inactivity of the corresponding methyl ester of farnesol (**6**, Table 2). Finally, in terms of designing a potential affinity column for farnesol binding proteins, the omega-hydroxy 9-thia compound (**40**, 0.1%) was 49-fold less active than its nonhydroxylated parent compound (**21**, Table 5). Similarly, all other farnesol analogs with a terminal/ $\omega$ -hydroxyl group were inactive (data not shown). Future studies will be directed toward the design of an affinity column for farnesol binding proteins.

### Discussion

We have examined 40 natural and synthetic analogs of farnesol with regard to their ability to block germ tube formation in *Candida albicans*. Twenty-two of the forty analogs exhibited QSM activity. Thus, farnesol itself is not a requisite for QSM activity; there is flexibility with


Table 5. Biological Activity of Farnesol Analogs with Sulfur Atoms at the 9 Position

Analog Number	X =	IC <sub>50</sub> (μM)	Relative Activity
21	n-butyl	23.8	4.94
22	Isobutyl	44.3	2.64
23	tert-butyl		0.86
24	n-pentyl	66.8	1.75
25	Benzyl	68.9	1.72
26	Phenyl	79.2	1.47

regard to the head group (Table 2), double bonds (Table 3), chain length (Tables 3 and 4), and the presence of sulfur and selenium heteroatoms in the farnesyl backbone (Tables 4–6). All of our assays involve adding analogs to cells programmed for GlcNAc-induced germ tube formation. Thus, if we assume that there is an intracellular target/receptor for farnesol, the exogenous farnesol must cross the cytoplasmic membrane and then bind to the target. Therefore, the administered level of farnesol or farnesol analog may not reflect the actual intracellular concentration available to the receptor or target. As a corollary, a farnesol analog could be inactive either because it has difficulty crossing the membrane or difficulty binding to the target. For instance, it is reasonable to suppose that the dihydroxy analog (**40**) and the analogs containing a basic nitrogen (**7** and **31**) might have difficulty crossing the cytoplasmic membrane. Our

Table 6. Biological Activity of Farnesol Analogs Containing Heteroatoms at the 4 or 9 Positions

Analog Number	X =	IC <sub>50</sub> (μM)	Relative Activity
29	CH <sub>2</sub>	24.4	4.80
17	S	79.1	1.47
30	Se	45.7	2.57 <sup>a</sup>
32	O		0.07
33	O (with methyl branch added back at 3-position)		0.51
18	SCH <sub>2</sub> - <sup>b</sup>	67.0	1.75
34	OCH <sub>2</sub> - <sup>b</sup>		0.38
31	NCH <sub>2</sub> - <sup>b</sup>		0.03



Analog Number	X =	Relative Activity
35		0.96

<sup>a</sup> Compound **30** was 33% *E* and 67% *Z* at the 6,7-double bond. If only the *E* isomer was active, it would have a relative activity of 7.72.

<sup>b</sup> **18**, **31**, and **34** have four carbons instead of three, between the head group hydroxyl and the heteroatom.

<sup>c</sup> Compounds **35** and **22** are identical except that **35** has 9-O while **22** has 9-S.

Table 7. Biological Activity of Hydroxy and Epoxide Analogs of Farnesol

Analog Number		IC <sub>50</sub> (μM)	Relative Activity
1		1.2	100
9	2,3-epoxide		0.38
36	10,11-epoxide <sup>a</sup>	68.8	1.72
37	10-hydroxyl <sup>b</sup>	68.5	1.72
38	6-hydroxyl <sup>b</sup>	79.2	1.47
39	Juvenile Hormone III		0.16
40			0.10

<sup>a</sup> Compound **36** is a modified (reduced) form of juvenile hormone III in which the carboxyl group has been reduced to a primary alcohol.

<sup>b</sup> Hydroxyls were introduced as racemic mixtures at the 10 (**37**) and 6 position (**38**) by hydroboration of the 10–11 and 6–7 double bonds, respectively.

focus on a putative farnesol binding protein is made with full realization that existing data do not yet prove the existence of farnesol binding proteins in *C. albicans*.

At present, virtually nothing is known about farnesol's mode of action in regulating fungal cell morphology. One of the purposes in examining this collection of farnesol analogs was to put constraints on the possible modes of action for farnesol. As a starting point, farnesol could bind to a specific receptor. This receptor could be either a fungal analog of the nuclear FXR receptor found in most higher eukaryotes [8, 9] or a different farnesol-specific receptor. However, a genomic search of *S. cerevisiae* and *C. albicans* failed to identify sequences similar to mammalian FXR receptors. Thus, if activity is mediated through a farnesol receptor, it is likely to be of a type not previously observed.

What can we infer about the farnesol binding pocket of the putative receptor? How are conformational space and topographical space related to molecular recognition? One approach to our structure-activity results is the linear approach based upon the three regions of farnesol which are altered: (i) The C<sub>1</sub> terminal hydroxyl group, (ii) the C<sub>1</sub>-C<sub>4</sub> "head group" region, and (iii) the C<sub>9</sub>-C<sub>12</sub> "tail" region. We have not yet analyzed enough analogs of the C<sub>5</sub>-C<sub>8</sub> "midchain" region to draw any useful conclusions. In this regard, with the exception of **30**, the central double bond of all the analogs (equivalent to the 6,7 double bond of farnesol) retained the *E* configuration of the starting material (usually geranyl bromide or chloride). It is tempting to suggest that the 6,7 double bond is critical for activity because compounds **13** (*E*) and **14** (*Z*), differing at the 2,3 double bond, had equivalent activities (Table 4).

The terminal hydroxyl group proved almost invariant. Although farnesoic acid and the amide (**2** and **3**) displayed activity, functional groups of similar size (aldehyde, methyl ester) or hydrogen-bonding ability (amine) possessed no QSM activity. In this regard, the reduced activity observed [1] for nerolidol (3,7,11-trimethyl-1,6,10-dodecatriene-3-ol) could reflect either the altered regiochemistry or increased steric bulk of the head group relative to the C<sub>1</sub> primary hydroxyl of farnesol. On the other hand, nerolidol differs from farnesol only in

a 1,3-allylic transposition of the hydroxyl and alkene groups, and it is possible that allylic isomerization to farnesol may be the source of the "activity" of nerolidol.

The rest of the head group region, however, proved fertile ground for analog development. A primary alcohol was retained as a fixed element in all designs. It is interesting to analyze the alkanol analogs based on the assumption that the role of the farnesol C<sub>1</sub>-C<sub>4</sub> region is to hold the alcohol in a particular register relative to the remainder of the molecule. The three-carbon span in **27** may be too short to allow the alcohol to occupy the same space as in farnesol, whereas the four-carbon span in **28** can achieve a farnesol-like disposition through a low-energy extended conformation and the longer five-carbon span in **29** can adopt a similar overall shape through introduction of a single gauche kink. As a corollary, the inactivity of **10** suggests that the presence of a C-3 methyl on the same five-carbon span prevents the assumption of a farnesol-like conformation. The subtlety of these interactions is further illustrated by comparing removal of the 3-methyl group for the all-carbon molecules (**10** versus **29**, 11-fold increase in activity), the sulfur-containing analogs (**15** versus **17**, 5-fold decrease in activity), and oxygen-containing analogs (**33** versus **32**, 7-fold decrease in activity).

The need for a tail region was clear from the complete lack of activity of the shorter (C<sub>10</sub>) geraniol [1]. Similarly, the lack of activity [1] of the diterpene (C<sub>20</sub>) geranylgeraniol could represent "too much" tail in terms of poor fit into a receptor or excess hydrophobicity. Replacement of the terminal 4-methyl-3-pentenyl unit of farnesol with an isobutyl ether (**35**) resulted in loss of activity, whereas the 10,11-epoxide (**36**) and the 10-hydroxyl (**37**) analogs retained activity. Similarly, the *n*-butyl and isobutyl thioethers (**21** and **22**) retained activity while the inactivity of a *tert*-butyl thioether (**23**) suggested intolerance for steric bulk in the C<sub>9</sub>-C<sub>10</sub> region.

A second approach to our structure-activity results is based on the implications of substituting heteroatoms into the farnesol backbone. Most of the analogs containing a thioether retained QSM activity (Tables 4 and 5). The exact chain length did not appear to be a critical variable. Compare the activities of **27**–**29** (Table 3) and

16–18 (Table 4). In the latter series, 16, 17, and 18 had two-, three-, and four-carbon spacers between the sulfur and the hydroxyl, respectively. We note three points of interest in activity comparisons among four pairs of molecules, 28 and 16, 29 and 17, 10 and 15, and 1 and 13/14, which are identical except for the replacement of CH<sub>2</sub> by sulfur. First, for four compounds (13/14, 16, and 17) introduction of the sulfur atom decreases QSM activity relative to the carbon-containing analog, whereas 15 displays 16-fold greater activity than the nonsulfur analog. Second, the mixed disulfide (19) also retains activity (Table 4). Thus, we have a sequence of three active compounds (29, 17, and 19) with nearly equivalent chain lengths but containing zero, one, and two sulfurs, respectively. The final point of note is that compound 15 was one of only nine analogs tested (8–10, 20, and 36–39 were the others) that possessed a chiral center. Compound 15 was prepared and assayed as a racemic mixture; it is likely that one of the two enantiomers would possess even greater activity.

Thus, both the all-carbon alkanols (27–29) and the thiaalkanols (16–18) retain significant activity. In theory, the corresponding O-ethers should combine the best features of the alkanols (similar C-O and C-C bond lengths) and the thiaalkanols (similar conformational preferences). However, none of the O-ethers had activity (Table 6). This outcome may be due to the greater polarity of the ethers as well as to an intramolecular H bond between the O-ether and the C-1 alcohol. This explanation is supported by a comparison between the inactive O-ether (32) and the highly active Se-ether (30). The results could also reflect the relative C-X bond lengths: C-Se > C-S > C-C > C-O.

A third approach to our structure-activity results is based on the role of alkenes in providing conformational constraints on the farnesol backbone. The three trisubstituted alkene subunits of farnesol each impart significant conformational constraints on neighboring linkages. In particular, allylic strain from the methyl groups at C<sub>3</sub>, C<sub>7</sub>, and C<sub>11</sub> precludes conformations which place the C<sub>1</sub>-O, C<sub>4</sub>-C<sub>5</sub>, or C<sub>8</sub>-C<sub>9</sub> bonds into juxtaposition with the methyl branches. Similarly, 1,2-strain disfavors conformations which juxtapose the C<sub>4</sub>-C<sub>5</sub> or C<sub>8</sub>-C<sub>9</sub> bonds with the C<sub>3</sub> or C<sub>7</sub> methyl branches, respectively. The importance of these alkene-induced conformational constraints may be reflected in the lack of activity of the 2,3-dihydrofarnesol (10) and the 2,3,6,7,10,11-hexahydro (saturated) farnesol (12). At the same time, the results from the head and tail analogs demonstrate that neither the C<sub>2</sub>-C<sub>3</sub> nor C<sub>10</sub>-C<sub>11</sub> double bonds are required for activity; structurally related thioethers retain activity (Tables 4 and 5). Given the juxtaposition of the activity retained by the thioethers versus that lost by removal of the double bonds in compounds 10 and 12, one can imagine three possible roles for the alkene units of farnesol: (i) fitting into a narrow cleft, (ii) precluding particular conformations and thereby organizing the main chain into the proper conformation for binding, or (iii) providing electron density or van der Waals surface for a particular interaction with the receptor.

Each of the ideas has attractive features, and of course, they are not mutually exclusive. The first idea of a narrow cleft cannot be endorsed or completely ruled

out from our results. The epoxy (9) and cyclopropane (8) analogs preserve much of the conformational constraints of the 2,3-alkene but significantly enlarge the cross-sectional area of the alkene. The 2,3 cyclopropane analog maintains activity, but the more polar 2,3 epoxide has lost activity (Table 3). The second idea in which each of three trisubstituted alkenes exerts significant conformational constraints on the surrounding region suggests an obvious role in providing bias toward particular conformers. This hypothesis is supported by our discovery that the QSM activity of commercial farnesols correlates closely with the fraction of the natural *E,E*-isomer (Table 1). The third idea in which the alkene units provide needed electron density fits with the strong activity of the thioethers. Replacement of either the head (Table 4) or tail (Table 5) alkene with a straight chain thioether maintains QSM activity. However, the activity of analogs containing linear methylene head groups (27–29) suggests that electron density in the form of an alkene or a thioether is not essential. Thus, in summary, the factors which seem necessary for farnesol's QSM activity and binding to a presumptive farnesol binding protein include: (i) a C-1 hydroxyl; (ii) a C-3 methyl group (but no larger); (iii) a hydrophobic tail; and (iv) the appropriate conformational constraints on backbone conformers as provided by the three, trisubstituted alkenes of farnesol. Factors which do not seem as critical include: (i) absolute chain length; (ii) the chemical structure of the C<sub>9</sub>-C<sub>12</sub> hydrophobic tail; and (iii) the origin of the needed conformational constraints in the backbone. S and Se heteroatoms are permitted.

### Significance

Farnesol is a quorum-sensing molecule in *Candida albicans* that acts to block the transition from yeasts to mycelia. It is widely agreed that this morphological transition is a critical feature of this organism's pathogenicity. A further understanding of the action of farnesol on a molecular level could lead to better control of this common human pathogen. To address this topic, we created a series of farnesol analogs and examined their ability to inhibit mycelial development. Taken together, our results provide four major advancements to the understanding of the molecular action of farnesol. (1) Of the four possible geometric isomers of farnesol, only the *E,E* isomer possesses QSM activity. (2) Structural analogs of farnesol that retain biological activity can be synthesized. In other words, farnesol itself is not essential for the activity seen in *C. albicans*. (3) Subtle changes in the structure of farnesol lead to significant changes in the activity. (4) These analogs indicate which parts of the molecule can be altered and still retain activity and which are essential for activity. This information may help in the development of second generation farnesol analogs with useful pharmacokinetic properties. For instance, studies using cyclization to achieve conformational constraint seem indicated. However, even the most active of the analogs tested had only 7.3% of the activity of *E,E*-farnesol, and thus they are unlikely to have any therapeutic potential as farnesol agonists in hosts

infected by *C. albicans*. However, if farnesol does prove to be a virulence factor for *C. albicans*, these analogs may prove to be effective antagonists for farnesol.

#### Experimental Procedures

##### Strain and Chemicals

*Candida albicans* A72 was obtained from Patrick Sullivan, University of Otago, Dunedin, New Zealand. A stock culture was grown in modified glucose-salts-biotin medium, washed in potassium phosphate buffer, and stored in the same buffer as previously described [1]. Commercial mixed isomers farnesol (Acros Organics and Sigma), *E,E*-farnesol (Sigma), and farnesol (Pfaltz and Bauer, Waterbury, CT) were stored at  $-20^{\circ}\text{C}$  with desiccant. Juvenile Hormone III, *E,E*-farnesyl bromide, and all-trans retinol (Sigma) were stored at  $-20^{\circ}\text{C}$ . Our fresh farnesol samples were roughly ten times more active than those we had reported previously [1], probably because this time we were scrupulous to exclude oxygen by resealing the pure farnesol oils under nitrogen and storing them with desiccation.

##### General Synthetic and Analytical Procedures

General procedures for synthesis and characterization of substrates follow. Experimental procedures and characterization data for individual compounds are found in the accompanying appendix. All reagents and solvents were used as supplied commercially, except tetrahydrofuran (THF; distilled from sodium/benzophenone),  $\text{CH}_2\text{Cl}_2$  (distilled from  $\text{CaH}_2$ ), hexamethylphosphoric triamide (HMPA; distilled from  $\text{CaH}_2$  and stored over 4 Å mol sieves), and *N,N*-dimethylformamide (DMF; stored over 4 Å sieves). Unless otherwise noted, reactions were run under a blanket of  $\text{N}_2$  in a round-bottom flask equipped with a magnetic stirrer. Except where noted, NMR spectra were taken as  $\text{CDCl}_3$  solutions at 300 MHz ( $^1\text{H}$ ) or 75 MHz ( $^{13}\text{C}$ ). Infrared spectra were acquired on neat films on a ZrSe crystal. Purification of most compounds was based upon air-driven (2–5 psi) flash chromatography on 230–400 mesh silica; the solvent system employed is listed for each compound. Thin-layer chromatography (TLC) employed silica (0.25 mm layer thickness) on glass plates; detection was accomplished with a hand-held UV lamp, iodine vapor, 1% aqueous  $\text{KMnO}_4$  (alkenes), or charring with a solution of ceric sulfate and ammonium molybdate in 10%  $\text{H}_2\text{SO}_4$  (most compounds). Analytical and semipreparative HPLC employed  $0.5 \times 25$  cm and  $2.1 \times 25$  cm silica columns, with detection by refractive index. Mass spectra were obtained at the Nebraska Center for Mass Spectrometry (Lincoln, NE). All prepared compounds were homogeneous by TLC,  $^1\text{H}$  NMR, and  $^{13}\text{C}$  NMR except for compound 30, which was 33% *trans* and 67% *cis* at the 6,7 double bond.

##### Bioassays of Farnesol and Related Compounds

The bioassays were performed in 25 ml Erlenmeyer flasks in a differentiation medium consisting of 11 mM imidazole, pH 6.5, 3 mM  $\text{MgSO}_4$ , 2.6 mM *N*-acetyl-*D*-glucosamine (GlcNAc) as the germ tube inducer, and either methanol (for a control) or a methanolic solution of the compound being tested. All solutions of farnesol in methanol were used immediately after preparation. Despite the fact that dilute aqueous solutions of farnesol can be stable for years [1], pure farnesol oils are highly susceptible to air oxidation resulting in modification of the 10,11-alkene unit. Our assays of the 10,11-epoxide and the 10-hydroxyl compounds (Table 7) confirm that oxidative modification of the 10,11-alkene is accompanied by a dramatic decrease in QSM activity. Prior to analysis, all compounds were dried, stored at  $4^{\circ}\text{C}$  for no more than 24 hr, and resuspended as a 25 mM stock solution in 100% methanol immediately before use. The final concentration of methanol in the bioassays was  $\leq 1\%$ . All compounds were tested at 10, 50, and 100  $\mu\text{M}$  for their ability to block germ tube formation. These concentrations are well below the 250–300  $\mu\text{M}$  levels at which farnesol itself does not impact the growth rate of *C. albicans* [1, 3]. Flasks were preincubated at  $37^{\circ}\text{C}$  for 20 min and then inoculated to  $5 \times 10^6$  cells/ml of *C. albicans* A72. Flasks were incubated at  $37^{\circ}\text{C}$  for 4 hr with shaking at 250 rpm on a New Brunswick Scientific Co. G2 shaker. After 4 hr, cells were examined by phase-contrast microscopy. At least 100 cells were counted for every flask and analyzed for percent germ tube formation. Com-

pounds which exhibit farnesol-like activity cause a shift from germ tubes to actively budding yeasts. Previous studies indicated that any lethal compounds or lethal concentrations instead gave phase dark, undifferentiated cells. None of analogs tested exhibited toxicity at concentrations up to 100  $\mu\text{M}$ .

##### Activity Calculations

Two measures of analog activity were employed. In the first, we compared the concentrations of farnesol and the analog necessary to lower the percent germ tubes formed to 50%. An analog is considered to be active if it was capable of reducing germ tube formation by 50% at the highest concentration tested. For inactive analogs, we used an exponential decay function to model the activities of the farnesol standard and the farnesol analogs according to the function  $G = G_0 \times e^{(b \times C)}$ , where  $G$  represents the percentage of germ tubes,  $C$ , the concentration of sample in the assay,  $G_0$ , the percentage of germ tubes when  $C = 0$ , and  $b$ , the steepness of the decay. At zero concentration, 95%–99% mycelia were observed for all samples, and therefore,  $G_0$  was fixed at 95. This allowed a single parameter,  $b$ , to be determined by the least-squares method using the Maple V program (Waterloo Maple, Waterloo, CA). A commercial sample of *E,E*-farnesol (Sigma) was chosen as the standard. The percentage activity for each analog was then determined by the ratio of the calculated  $b$  values from the regression algorithm. Results are presented in the tables as “relative activity.”

##### Supplemental Data

Experimental procedures and characterization (TLC,  $^1\text{H}$  and  $^{13}\text{C}$  NMR, and IR) for compounds 7, 11, 13–19, 21–23, 25, 27–35, and 37–38 can be found at <http://www.chembiol.com/cgi/content/full/10/8/743/DC1>; references to preparations of known compounds (3, 6, 8–10, 12, 26, and 36) are also provided.

##### Acknowledgments

This work was supported by grants from the National Science Foundation (MCB-0110999) and the University of Nebraska Tobacco Settlement Biomedical Research Enhancement Fund. We thank Sara Basiaga for assistance with GC/MS and Bruce D. Hammock for pointing out the tendency of farnesol oils to undergo air oxidation.

Received: January 2, 2003

Revised: June 25, 2003

Accepted: June 26, 2003

Published: August 22, 2003

##### References

1. Hornby, J.M., Jensen, E.C., Lisec, A.D., Tasto, J.J., Jahnke, B., Shoemaker, R., Dussault, P., and Nickerson, K.W. (2001). Quorum sensing in the dimorphic fungus *Candida albicans* is mediated by farnesol. *Appl. Environ. Microbiol.* 67, 2982–2992.
2. Fuqua, W.C., Winans, S.C., and Greenberg, E.P. (1994). Quorum sensing in bacteria: the Lux R-Lux I family of cell density-responsive transcriptional regulators. *Microbiol. Rev.* 58, 250–275.
3. Ramage, G., Saville, S.P., Wickes, B.L., and Lopez-Ribot, J.L. (2002). Inhibition of *Candida albicans* biofilm formation by farnesol, a quorum-sensing molecule. *Appl. Environ. Microbiol.* 68, 5459–5463.
4. Lo, H.J., Köhler, J.R., DiDomenico, B., Loebenberg, D., Cacciapuoti, A., and Fink, G.R. (1997). Nonfilamentous *C. albicans* mutants are avirulent. *Cell* 90, 939–949.
5. Vaidya, S., Bostedor, R., Kurtz, M.M., Bergstrom, J.D., and Bansal, V.S. (1998). Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A. *Arch. Biochem. Biophys.* 355, 84–92.
6. Oh, K.-B., Miyazawa, H., Naito, T., and Matsuoka, H. (2001). Purification and characterization of an autoregulatory substance capable of regulating the morphological transition in *Candida albicans*. *Proc. Natl. Acad. Sci. USA* 98, 4664–4668.

7. Matsuoka, H., and Oh, K-B. (2001). Bio Giken K.K., August, 2001. Compound to regulate the morphological transition of dimorphic *Candida*. United States Patent Number 6,271,267.
8. Edwards, P.A., and Ericsson, J. (1999). Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. *Annu. Rev. Biochem.* 68, 157–185.
9. Forman, B.M., Goode, E., Chen, J., Oro, A.E., Bradley, D.J., Perlmann, T., Noonan, D.J., Burka, L.T., McMorris, T., Lamph, W.W., et al. (1995). Identification of a nuclear receptor that is activated by farnesol metabolites. *Cell* 81, 687–693.